Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients

Migraine Disorders Clinical Trial

Official title:

A Double-blind, Randomized, Placebo-controlled Clinical Trial to Confirm the Rationale of the ASA + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02183688
• Other study ID #: 155.8
• Status: Completed
• Phase: Phase 3
• First received: July 7, 2014
• Last updated: July 7, 2014
• Start date: September 1998

Study information

• Verified date: July 2014
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

To confirm the combination rationale for the combination of ASA + paracetamol + caffeine compared with the combination of ASA + paracetamol and the individual substances ASA, paracetamol, caffeine, and placebo administered orally to headache patients for two headache episodes

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1889
• Est. primary completion date: January 2003
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Female or male out-patients aged between 18 and 65 years

2. Diagnosis: Headache

1. Tension type headache according to international headache society (IHS) Headache Classification 2.1 (2.1.1 and 2.1.2) and/or

2. Migraine according to IHS Headache Classification 1.1, 1.2.1 or

3. Either a) or b), but cannot be distinctly classified

3. The patient normally treats his/her headache successfully with non-prescription analgesics

4. He/She has been suffering from headache for 12 months at least

5. The headache first occurred before the age of 50 years

6. During the previous three months, the patient has suffered from headache twice a month at least

7. Informed consent according to §§ 40, 41 of the german medicines act and Good Clinical Practice (GCP)

8. The patient seems likely to comply

Exclusion Criteria:

1. The patient treats his/her headache with prescription-only analgesics or migraine remedies

2. The patient requires higher single doses of non-prescription analgesics to treat his/her headache than indicated in the patient information leaflet (e.g. more than 2 tablets of Thomapyrin tablets)

3. The patient normally treats his/her headache with non-prescription analgesics in effervescent tablet form

4. The patient normally takes his/her non-prescription analgesics immediately at the onset of the first signs of a headache episode

5. Headache occurs on more than 10 days per month

6. The typical, untreated headache normally lasts less than 4 hours without treatment

7. Women with a close association between the occurrence of headache and menstruation (menstrual migraine)

8. Concomitant treatment with prescription-only and/or non-prescription analgesics

9. Previous or concomitant treatment with antidepressants or antipsychotic medicines (previous treatment = within the previous 4 weeks)

10. Previous or concomitant treatment with anti-rheumatic or anti-inflammatory drugs that may influence the headache symptoms (previous treatment = within the previous 4 days)

11. Treatment of concomitant illnesses with drugs containing ASA (above a daily dose of 100 mg per day), paracetamol or caffeine (e.g. for feverish common cold, etc.)

12. Migraine prophylaxis or administration of drugs, indicated for any other reasons that influence headache symptoms, e.g.

Propanolol, Metoprolol, Flunarizine, Cyclandelate, Valproic acid, Serotonin antagonists (pizotifen, methysergide, lisuride), Ergotamine, Dihydroergotamine, Benzodiazepines, Magnesium, Monoamine oxidase inhibitors

13. Concomitant treatments with anti-emetics

14. Drug abuse connected with the headache (defined as the administration of analgesics or other drugs for the treatment of acute headache on more than 10 days per month)

15. Alcohol or drug abuse as defined by diagnostic and statistical manual of mental disorders (DSM-IV)

16. Pregnancy and lactation

17. Gastrointestinal ulcers

18. Pathologically increased bleeding tendency

19. Glucose-6-phosphate dehydrogenase deficiency

20. Hypersensitivity to paracetamol, caffeine, ASA, salicylates, and other anti-inflammatory/anti-rheumatic agents or other allergenic substances that are relevant to the clinical trial

21. Bronchial asthma

22. Concomitant treatment with anticoagulants (e.g. coumarin derivates, heparin)

23. Clinically relevant chronic or recurrent gastrointestinal symptoms

24. Clinically relevant liver disorders

25. Clinically relevant pre-existing renal damage

26. Gilbert's syndrome

27. Not successfully treated hyperthyroidism

28. Simultaneous participation in another clinical trial

29. Participation in another clinical trial within 4 weeks of entering this study

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Migraine Disorders

Intervention

Drug:
• Low dose ASA

• High dose ASA

• Low dose paracetamol

• High dose paracetamol

• Caffeine

• Placebo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Calculated time to 50% pain relief, based on the pain intensity evaluated on a visual analogue scale (VAS)		30 min., 1, 2, 3 and 4 hours after administration of the study medication	No
Secondary	Percentage of patients with 50 % pain relief, evaluated on a VAS		At least 2 hours after administration of the study medication	No
Secondary	Percentage of patients with 50 % pain relief, evaluated on a VAS		At least 30 min., 1, 3, and 4 hours after administration of the study medication	No
Secondary	Pain intensity, evaluated on a VAS		30 min., 1, 2, 3 and 4 hours after administration of the study medication	No
Secondary	Ratio of weighted sum of pain intensity difference scores to maximum achievable sum of pain intensity differences (%SPIDweighted), evaluated on a VAS		Up to the end of the study	No
Secondary	Extent of impairment of daily activities, evaluated on a 4-grade verbal scale (VRS)		Before, 30 min., 1, 2, 3 and 4 hours after administration of study drug	No
Secondary	Duration of headache		Up to 48 hours after onset of each headache episode	No
Secondary	Global assessment of efficacy by the patient, evaluated on a 4-grade VRS		Within 12 hours after study drug administration	No
Secondary	Global assessment of tolerability by the patient, evaluated on a 4-grade VRS		Within 12 hours after study drug administration	No
Secondary	Number of patients with adverse events		Up to the end of the study	No
Secondary	Global assessment of tolerability by the investigator, evaluated on a 4-grade VRS		After each administration of study drug during the treatment phase	No

External Links

•   Link